L-2 | L-2Rα | Il-2Rβ | IL-2Rγ | |||||
---|---|---|---|---|---|---|---|---|
Group (no. of cases) | Positive samples | Optical density | Positive samples | Optical density | Positive samples | Optical density | Positive samples | Optical density |
Human thymus (4) | 4 (100%) | 12.1 ± 1.2 | 4 (100%) | 10.07 ± 1.47 | 4 (100%) | 14.33 ± 2.1 | 4 (100%) | 13.21 ± 0.89 |
Fibrocystic benign lesions (13) | 5 (38.5%) | 4.02 ± 0.37a | 7 (53.8%) | 7.13 ± 0.19a | 4 (30.8%) | 2.05 ± 0.35a | 6 (46.1%) | 15.40 ± 2.4a |
In situ carcinomas (17) | 7 (41.2%) | 20.47 ± 2.42b | 6 (35.3%) | 20.30 ± 1.29b | 6 (35.3%) | 28.90 ± 1.15b | 7 (41.2%) | 25.05 ± 2.5b |
Infiltrating carcinomas (35) | 29 (82.9%) | 26.93 ± 4.82c | 21 (60.0%) | 52.92 ± 4.77c | 28 (80.0%) | 31.22 ± 6.80b | 28 (80.0%) | 40.82 ± 5.78c |
Lymph node infiltration (13) | 11 (84.6%) | 28.24 ± 4.9c | 11 (84.6%) | 54.41 ± 4.8c | 10 (76.9%) | 28.94 ± 5.66b | 12 (92.3%) | 38. 8 ± 6.12c |
Neither lymph node infiltration nor metastasis (22) | 18 (81.8%) | 26.06 ± 4.89c | 10 (45.4%) | 51.55 ± 4.79c | 18 (81.8%) | 32.28 ± 6.80b | 16 (72.7%) | 42.16 ± 6.93c |